Docmode Health Technologies Ltd IPO Timeline

Docmode Health Technologies Ltd IPO opens on 25-Jan-2024, and closes on 29-Jan-2024. The Docmode Health Technologies Ltd IPO bid date is from 25-Jan-2024 to 29-Jan-2024. The Cut-off time for UPI Mandate confirmation is 12 P.M. on the next day of issue closing day.

Event Date
Docmode Health Technologies Ltd IPO Opening Date 25-Jan-2024
Docmode Health Technologies Ltd IPO Closing Date 29-Jan-2024
Basis of Allotment 31-Jan-2024
Initiation of Refunds 01-Feb-2024
Credit of Shares to Demat 01-Feb-2024
Docmode Health Technologies Ltd IPO Listing Date 02-Feb-2024

Docmode Health Technologies Ltd IPO Lot Size

Docmode Health Technologies Ltd IPO lot size is 1600 shares. A retail-individual investor can apply for up to 1 lots (1600 shares or 126400).

Application Lots Shares Amount
Minimum 1 1600 ₹126400
Maximum 1 1600 ₹126400

Docmode Health Technologies Ltd IPO Details

Docmode Health Technologies Ltd IPO Date 25-Jan-2024 to 29-Jan-2024
Docmode Health Technologies Ltd IPO Face Value Shares of ₹10 per share
Docmode Health Technologies Ltd IPO Price ₹79 per share
Docmode Health Technologies Ltd IPO Lot Size 1600
Issue Size Shares of ₹10 (aggregating up to ₹6.71 Cr)
Fresh Issue Shares of ₹10 (aggregating up to ₹6.71 Cr)
Offer for Sale -
Issue Type Fixed Price - SME
Listing At NSE - SME
QIB Shares Offered -
Retail Shares Offered -
NII (HNI) Shares Offered -
Company Promoters Paulson Paul Thazhathedath, Hans Albert Lewis.

Objects of the Issue

The company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

  • 1 Purchase of IT Infrastructure & Operating Systems
  • 2 Meeting Incremental Working Capital Requirements
  • 3 General Corporate Purposes

Company Financials

Docmode Health Technologies Ltd Financial Information (Restated)

Period Ended Total Assets Total Revenue Profit After Tax
03-2023 17.01 32.97 1.95
03-2022 10.09 12.44 0.92
03-2021 5.67 7.10 0.55
Amount in ₹ Crore
  • Technology driven, asset light & scalable business model.
  • Strong network effects resulting in growth business verticals.
  • Experience in the education business and professionally qualified human capital.
  • Diversified and integrated education products, services and content offerings.
  • Continue offering new course/lecture content.
  • The company is dependent on the relationships with healthcare professionals, and its business and financial results could be to an extent impacted if the company is not able to engage such healthcare professionals on a regular basis.
  • The company ability to retain the present number of learners and professionals serviced by it and attract new learners and professionals is dependent upon various factors including its reputation and the company ability to maintain a high level of service quality. Any failure by it to retain or attract learners and professionals may impact the business and its revenues.
  • The Company is yet to place orders for the purchase of IT infrastructure and operating system. Any delay in placing orders or procurement of such machinery may delay the schedule of implementation.
  • The business in which its operate is specifically regulated. The central and state governments may change the existing regulations or introduce a new regulatory framework in the future. The impact of such changes or new regulations on the business cannot be ascertained presently and may affect the company business adversely in the future.
  • The company's success depends significantly on the company ability to continue to innovate and implement technological advances. If its are unable to keep pace with evolving technology and user preferences, the company business, results of operations and prospects may be adversely affected.
  • Strong competition in the business of providing professional medical learning could also decrease its market share and compel it to reduce course fees or provide higher discounts on the course fees. This may have a material adverse impact on the number of learners and health care professionals enrolled with it, revenues and profitability.
  • Any disruption in its information technology systems may adversely affect its business, results of operations and prospects.
  • The company may not be able to renew, maintain or obtain the requisite permits and approvals in future and this may affect the company business and operations.
  • The company has issued equity shares during the last one year at a price that may be below the Issue Price.
  • Its Subsidiary Company have incurred losses in past.
  • Its may be unable to enforce the company rights under some of the agreements on account of inadequate stamping and not registering the agreements or other reasons.
  • The company depends heavily on its senior management team, and loss of the services of one or more of the key executives or a significant portion of the company local management personnel could weaken its management team and adversely affect the company financial condition and prospects.
  • The company is dependent upon affiliated medical institutions for its business. Any reduction or interruption of a key medical institution it may have an adverse impact on the revenues and operations of the Company.
  • The companyh has in the past entered into related party transactions and may continue to do so in the future.
  • The Company had availed unsecured loans with banks and financial institutions which is repayable on demand. Any demand from the lender for repayment of such unsecured loan may affect its cash flow and financial condition.
  • All properties which the company use for its business including the Registered Office have been leased, including properties leased from related parties. In the event of termination or non- renewal of the leases, the company business and revenues may be adversely affected.
  • The Promoters and Promoter Group will continue to retain majority shareholding in it after the Issue, which will allow them to exercise significant influence over it and potentially create conflicts of interest.
  • The Promoters and Directors may have interest in the Company, other than reimbursement of the Directors (including the company Promoters) and key management personnel may have interests other than reimbursement of expenses incurred and normal remuneration or benefits in the Company.
  • The intellectual property developed by it has not been registered under the patent or copyright laws of India.
  • The Company requires significant amount of working capital for a continuing growth. Its inability to meet the company working capital requirements may adversely affect its results of operations.
  • The company insurance cover may be inadequate to fully protect it from all losses and may in turn adversely affect its financial condition.
  • The Company, Directors and Promoter are involved in legal proceedings. Any adverse outcome in such proceedings may have an adverse impact on its reputation, business, financial condition, results of operations and cash flows.
  • Its may not be able to sustain effective implementation of the company business and growth strategies.
  • Reliance has been placed on declarations furnished by Paulson Paul Thazhathedath and Hans Albert Lewis, the Directors, for details of their profile included in this Draft Prospectus.
  • The company ability to pay dividends in the future will depend, inter alia, upon available financial resources, investment requirements and taking into account optimal shareholder returns.
  • The company funding requirements and the proposed deployment of Net Proceeds are not appraised by any independent agency are based on management estimates and may be subject to change based on various factors, some of which beyond its control. Any changes in the estimated funding requirements could affect the company business and results of operations.
  • The Company has negative cash flows from its operating, investing and financing activities in the past, details of which are given below. Sustained negative cash flow could impact its growth and business.
  • There is no monitoring agency appointed by the Company and the deployment of funds are at the discretion of its management and our Board of Directors, though it shall be monitored by the Audit Committee. The objects of the Offer for which funds are being raised have not been appraised by any bank or financial institution and are based on management estimates.
  • The company may be unable to sufficiently obtain, maintain, protect, or enforce the company intellectual property and other proprietary right.
  • If the company inadvertently infringe on the intellectual property of others, its may be subjected to legal action and the company business and reputation may be adversely affected.
  • The company funding requirements and the proposed deployment of Net Proceeds are not appraised by any independent agency are based on management estimates and may be subject to change based on various factors, some of which beyond its control. Any changes in the estimated funding requirements could affect the company business and results of operations.
  • One of the objects of the Issue include funding working capital requirements of the Company, which are based on certain assumptions and estimates.
  • The company could be harmed by employee misconduct or errors that are difficult to detect and any such incidences could adversely affect its financial condition, results of operations and reputation
  • Any non-compliance or delay in RoC filings may expose it to penalties from the regulators.
  • Significant disruptions in the information technology systems or breaches of data security could adversely affect its business and reputation.
  • Some of the information of the Company mentioned in the Business chapter are system driven and is taken from the dashboard of the Company.
  • Industry information of the Company included in this Draft Prospectus has been derived from different industrial association and other governmental sources and reports. There can be no assurance that such third-party statistical, financial and other industry information is either complete or accurate.
  • Brand building strategy that covers a judicial mix of print, video, digital and social media.
  • Develop and expand its publishing research articles and content development.
  • The Company will focus on healthcare services platform where the patients can interact with doctors for educating and support.
  • Create a practice tool like iNutrimon in every speciality.

Docmode Health Technologies Ltd IPO Promoter Holding

Pre Issue Share Holding 65.0%
Post Issue Share Holding 47.42%

Docmode Health Technologies Ltd IPO Subscription Status (Bidding Detail)

The Docmode Health Technologies Ltd IPO is subscribed - times on Jan 29, 2024 05:00:00 PM. The public issue subscribed - times in the retail category, - times in the QIB category, and - times in the NII category. Check Day by Day Subscription Details (Live Status)

Category QIB NII Retail Employee Total
Subscription (times) - - - - -

Docmode Health Technologies Ltd IPO Prospectus

Docmode Health Technologies Ltd IPO Listing Date

Listing Date 02 Feb 24
BSE Script 79225
NSE Symbol DHTL
Listing In NSE - SME
ISIN INE0OGG01015
IPO Price ₹79
Face Value ₹10

Docmode Health Technologies Ltd IPO Registrar

Bigshare Services Pvt Ltd

Phone: +91 22 6263 8200
Email: ipo@bigshareonline.com
Website: www.bigshareonline.com

Docmode Health Technologies Ltd IPO Lead Manager(s)

  1. Fedex Securities Pvt Ltd

FAQs on Docmode Health Technologies Ltd IPO

Docmode Health Technologies Ltd IPO, which opens for subscription from 25-Jan-2024 to 29-Jan-2024 has an issue size of ₹6.71 crore. The issue type is book building issue.

In case of pre-apply, your IPO order will be placed on the Exchange as soon as the official bidding for Docmode Health Technologies Ltd IPO begins. You will receive a UPI request within 24 hours after the bidding period opens.

Docmode Health Technologies Ltd IPO Opens for subscription from 25-Jan-2024 to 29-Jan-2024.

The lot size of Docmode Health Technologies Ltd is 1600 shares. Retail investors can subscribe to minimum 1 lot and maximum 1 lots. The minimum and maximum application value is ₹126400 and ₹126400 respectively.

Allotment date for Docmode Health Technologies Ltd is 31-Jan-2024 and refund of application amount (in case allotment is not received) will begin from 01-Feb-2024. If your allotment goes through, then shares will be credited in your Demat account by 01-Feb-2024.

The registrar for Docmode Health Technologies Ltd IPO is Bigshare Services Pvt Ltd . You can check your IPO allotment status on the registrar's website.

The shares of Docmode Health Technologies Ltd are proposed to be listed on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Power your investments with our smart trading platforms

mobilefooterimg
  • app_download_icon_img
    5 million+
    App downloads
  • 1_Click_icon_img
    1-Click
    Order Placement
  • higherreturns_icon_img
    1,316 Crore+
    Average Daily Turnover